MANGOCEUTICALS, INC. (MGRX): Entry into a Material Definitive Agreement
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT THIS BUSINESS COMBINATION AGREEMENT (this “ Agreement ”) is made as of July 29, 2026 (the “ Execution Date ”), AMONG: MANGOCEUTICALS, INC. , a corporation incorporated under the Laws of the Sta
How this was made
The 30-second read
Why it matters
This disclosure can change deal-risk expectations and near-term trading behavior due to stated transaction structure, the 96% post-completion equity outcome (before PIPE), and the requirement for PIPE financing and later Nasdaq cap removal approvals.
Market read
A newly executed M&A-style definitive agreement plus PIPE and Nasdaq approval conditions is a tradable catalyst for MGRX, with likely volatility around deal progression and financing/approval milestones.
What to watch
Key trading drivers are not shown in the excerpt: PIPE size/terms, termination rights, deal valuation, and any regulatory or shareholder vote thresholds that could delay or derail completion.
Background
The filing is an SEC Form 8-K reporting entry into a material definitive agreement for a business combination between Mangoceuticals (Nasdaq: MGRX) and Nuclea Energy, using a Canadian exchangeable share structure.
Ticker impact
Mangoceuticals entered a material definitive business combination agreement with Nuclea, including an exchangeable share structure and PIPE financing conditions.
Likely volatility around deal terms, PIPE closing conditions, and subsequent shareholder/Nasdaq approval milestones.
An 8-K business combination agreement is a primary disclosure that can re-rate risk and timing, but the excerpt does not provide deal value, consideration mechanics beyond the 96% exchange, or definitive closing certainty.
Market effects
Could increase attention on nuclear-technology commercialization pathways and SPAC-like exchangeable structures, but the excerpt is deal-structure focused rather than technology milestones.
Primarily US-listed Nasdaq process risk (Nasdaq cap removal and listing application) with Canadian counterparty mechanics.
Limited based on the excerpt; the transaction is cross-border but not tied to broader macro or regulatory actions.
Counterpoint
The agreement may not translate into closing certainty if PIPE terms, approvals, or exchangeable-share mechanics face friction, so the market may fade the initial filing reaction.
Key entities
- public_companyMangoceuticals, Inc.
US-listed Nasdaq Capital Market company (MGRX) entering the definitive business combination agreement.
- companyNuclea Energy Inc.
Canadian company developing advanced nuclear technology, including its Morpheus Microreactor, and the counterparty in the transaction.
- investor_groupPIPE Investors
Parties expected to fund PIPE financing on the effective date, a condition to closing.
- executiveJacob D. Cohen
Mango’s CEO whose employment agreement is to be terminated on the effective date, with release and consulting agreements executed.
